Mandate

Vinge advises Trill Impact and ID North in connection with the acquisition of Pulsen Integration's IAM business

Vinge advises Trill Impact and its portfolio company ID North in connection with the acquisition of Pulsen Integration's Identity Access Management (IAM) business.

In total, 35 employees from Pulsen Integration in Sweden and Finland will become part of ID North, which operates within IAM and cyber security, providing IT consulting services, resale and in-house development of IT products with its base in Stockholm. At the same time, Pulsen Group becomes a shareholder in the parent company European ID Security, which includes ID North and Arctic Group. After the transaction, ID North consists of 65 employees in Sweden and Finland.

Vinge's team mainly consisted of Christina Kokko, Matthias Pannier, Samra Baytar, Nina Gransäter, Linus Adolfsson (M&A), Isabell Nielsen, Jolene Reimerson, Lisa Hörnqvist, Karolina Fuhrman (Commercial Agreements, IT & GDPR), Åsa Gotthardsson, Emil Lindwall (Employment), Arvid Axelryd (IP), Frida Ställborn (Real Property), Ulf Pyk (Banking and Finance), Ellinore Boström Andersson and Ellinor Gyllenhammar (Project Assistants).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026